Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,088,236
  • Shares Outstanding, K 140,663
  • Annual Sales, $ 599,670 K
  • Annual Income, $ 273,740 K
  • 60-Month Beta 1.91
  • Price/Sales 15.14
  • Price/Cash Flow 20.17
  • Price/Book 6.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.19
  • Number of Estimates 8
  • High Estimate 1.39
  • Low Estimate 0.84
  • Prior Year 2.42
  • Growth Rate Est. (year over year) -50.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.36 +18.86%
on 11/07/19
65.67 -1.61%
on 12/06/19
+9.01 (+16.21%)
since 11/06/19
3-Month
53.34 +21.13%
on 10/24/19
67.31 -4.01%
on 09/13/19
+2.86 (+4.63%)
since 09/06/19
52-Week
48.27 +33.85%
on 12/24/18
86.58 -25.38%
on 04/08/19
+8.56 (+15.27%)
since 12/06/18

Most Recent Stories

More News
Akcea Announces Appointment of New Chief Operating Officer

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company as chief operating officer. In this role, Mr....

AKCA : 17.64 (+0.17%)
IONS : 64.61 (+0.12%)
Ionis Pharmaceuticals to hold technology webcast

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Friday, December 13th at 11:00 a.m. Eastern Time to take a deep dive into antisense technology, Ionis' proprietary...

IONS : 64.61 (+0.12%)
SmarTrend Watching for Potential Pullback in Shares of Ionis Pharmaceut After 2.39% Gain

Ionis Pharmaceut (NASDAQ:IONS) traded in a range yesterday that spanned from a low of $61.76 to a high of $63.22. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high...

IONS : 64.61 (+0.12%)
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase...

AKCA : 17.64 (+0.17%)
IONS : 64.61 (+0.12%)
Surging Earnings Estimates Signal Upside for Ionis Pharmaceuticals (IONS) Stock

Ionis Pharmaceuticals (IONS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

IONS : 64.61 (+0.12%)
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the closing of the exclusive licensing...

AKCA : 17.64 (+0.17%)
IONS : 64.61 (+0.12%)
PFE : 38.29 (+0.68%)
Antisense Therapeutics Announces Additional preliminary data from the ATL1102 Phase II DMD trial presented at the 2019 Action Duchenne International Conference

Antisense Therapeutics (ASX: ANP/OTC: ATHJY) is pleased to advise that additional preliminary data analyses from the seven patients who have completed their 24 weeks of dosing in the ATL1102 Phase II DMD...

ATHJF : 0.0530 (-9.56%)
IONS : 64.61 (+0.12%)
Akcea Therapeutics to Present at Upcoming Investor Conferences

Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today...

AKCA : 17.64 (+0.17%)
IONS : 64.61 (+0.12%)
Ionis Pharmaceuticals to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:

IONS : 64.61 (+0.12%)
Ionis Pharmaceuticals: 3Q Earnings Snapshot

CARLSBAD, Calif. (AP) _ Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported third-quarter net income of $26 million, after reporting a loss in the same period a year earlier.

IONS : 64.61 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade IONS with:

Business Summary

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.

See More

Key Turning Points

2nd Resistance Point 66.15
1st Resistance Point 65.38
Last Price 64.61
1st Support Level 64.13
2nd Support Level 63.65

See More

52-Week High 86.58
Fibonacci 61.8% 71.95
Fibonacci 50% 67.43
Last Price 64.61
Fibonacci 38.2% 62.91
52-Week Low 48.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar